I think that to say "If Covid P3 fails, then CYDY

I think that to say "If Covid P3 fails, then CYDY is still cheap for the HIV and cancer indications" is the understatement of the month, as the share price will crater for MONTHS and while we do know that HIV will be approved, eventually, NOTHING will happen with that until a BLA is filed (somewhere! anywhere!) and we are at many months from that, let alone the time the FDA will need to review it, etc.

Cancer? Who knows how far off that is. If Covid fails, this becomes a far longer term investment than many of us had planned, given how "close" we were to filing the BLA here in the US and how far we actually seem to be.

Y'all can "thumbs down" facts all you want...doesn't make them less factual.